We showed that lenalidomide therapy leads to progression of TP53-mutant CH, which precedes t-MN and t-ALL, while discontinuation of lenalidomide stabilizes CH and may lead to regression of high-risk clones. The gene discussed is TP53; the disease is cyclic hematopoiesis.